Context Therapeutics Inc. (CNTX) 10-Year Financial Performance & Capital Metrics

CNTX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutContext Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Show more

Revenue $0
EBITDA -$30M -19.4%
Net Income -$27M -11.5%
EPS (Diluted) -0.46 +69.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -49.89% +51.5%
ROIC -
Debt/Equity 0.00
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 91 (top 9%)
✓Trading at only 0.9x book value

✗Weaknesses

✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM12.31%

EPS CAGR

10Y-

5Y-

3Y-

TTM67.08%

ROCE

10Y Avg-63.53%

5Y Avg-63.53%

3Y Avg-66.8%

Latest-55.8%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.45	53.21	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	11.82B	44.08	25.05	18.49%	29.63%	31.37%	5.36%	0.09
INBXInhibrx Biosciences, Inc.	1.07B	73.28	0.63	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.24B	6.55	-3.10		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.38B	7.94	-3.36	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	987.53M	10.14	-5.54			-33.24%		0.01
ZLABZai Lab Limited	2.07B	18.72	-7.20	49.59%	-46.83%	-27.21%		0.18
TNGXTango Therapeutics, Inc.	1.41B	10.44	-8.77	15.17%	-151.15%	-62.81%		0.18

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-
Operating Expenses+	5.38M	2.57M	10.53M	15.38M	25.07M	29.92M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	2.96M	930.67K	3.63M	7.79M	7.29M	7.22M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	2.41M	1.64M	3.81M	7.09M	17.78M	22.7M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	3.09M	500K	0	0
Operating Income+	-5.38M	-2.57M	-10.53M	-15.38M	-25.07M	-29.92M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	0.52%	-3.09%	-0.46%	-0.63%	-0.19%
EBITDA+	-5.38M	-2.57M	-10.39M	-15.37M	-25.06M	-29.91M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	0.52%	-3.04%	-0.48%	-0.63%	-0.19%
D&A (Non-Cash Add-back)	0	0	0	9.27K	12.04K	10.88K
EBIT	-5.28M	-2.57M	-10.39M	-14.88M	-25.07M	-29.92M
Net Interest Income+	-1.1M	-661K	-64.17K	0	1.16M	3.2M
Interest Income	1.1K	661	64	547.27K	1.16M	3.2M
Interest Expense	1.1M	661.22K	64.24K	547.27K	0	0
Other Income/Expense	-1.01M	9.22M	68.95K	545.26K	1.11M	3.2M
Pretax Income+	-6.38M	6.64M	-10.46M	-14.84M	-23.96M	-26.73M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-6.38M	6.64M	-10.46M	-14.84M	-23.96M	-26.73M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	2.04%	-2.57%	-0.42%	-0.62%	-0.12%
Net Income (Continuing)	-6.38M	6.64M	-10.46M	-14.84M	-23.96M	-26.73M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.68	-0.80	-3.69	-0.93	-1.50	-0.46
EPS Growth %	-	-0.18%	-3.61%	0.75%	-0.61%	0.69%
EPS (Basic)	-0.68	0.61	-3.69	-0.93	-1.50	-0.46
Diluted Shares Outstanding	10.96M	10.96M	2.83M	15.97M	15.97M	58.42M
Basic Shares Outstanding	10.96M	10.96M	2.83M	15.97M	15.97M	58.42M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	239.61K	349.71K	51.26M	37.85M	16.05M	97.9M
Cash & Short-Term Investments	226.6K	341.04K	49.64M	35.5M	14.45M	94.43M
Cash Only	226.6K	341.04K	49.64M	35.5M	14.45M	94.43M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	2.36M	1.6M	3.47M
Total Non-Current Assets+	33.94K	117.63K	50.39K	112.28K	15.52K	230.78K
Property, Plant & Equipment	0	0	0	79.53K	15.52K	230.78K
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	50.39K	0	0	0
Other Non-Current Assets	33.94K	117.63K	0	32.75K	0	0
Total Assets+	273.55K	467.34K	51.31M	37.97M	16.06M	98.13M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	0.71%	108.78%	-0.26%	-0.58%	5.11%
Total Current Liabilities+	24.11M	9.55M	3.03M	3.21M	4.19M	2.75M
Accounts Payable	2.07M	2.71M	1.83M	936.33K	2.38M	1.45M
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	21.84M	5.88M	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	0	0	85.53K	853.51K	661.3K	941.7K
Current Ratio	0.01x	0.04x	16.90x	11.80x	3.83x	35.62x
Quick Ratio	0.01x	0.04x	16.90x	11.80x	3.83x	35.62x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	126K	7.84M	0	0	0	112.06K
Long-Term Debt	0	69.04K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	112.06K
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	126K	7.77M	0	0	0	0
Total Liabilities	24.23M	17.39M	3.03M	3.21M	4.19M	2.86M
Total Debt+	21.84M	5.95M	0	55.08K	0	219.38K
Net Debt	21.62M	5.61M	-49.64M	-35.44M	-14.45M	-94.21M
Debt / Equity	-	-	-	0.00x	-	0.00x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-4.89x	-3.89x	-163.85x	-28.11x	-	-
Total Equity+	-23.96M	-16.92M	48.27M	34.76M	11.87M	95.27M
Equity Growth %	-	0.29%	3.85%	-0.28%	-0.66%	7.03%
Book Value per Share	-2.19	-1.54	17.03	2.18	0.74	1.63
Total Shareholders' Equity	-23.96M	-16.92M	48.27M	34.76M	11.87M	95.27M
Common Stock	324	332	15.97K	15.97K	15.97K	89.7K
Retained Earnings	-25.44M	-18.8M	-29.25M	-44.09M	-68.05M	-94.78M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.84M	-1.03M	-8.8M	-13.55M	-21.05M	-14.56M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	0.64%	-7.51%	-0.54%	-0.55%	0.31%
Net Income	-6.38M	6.64M	-10.46M	-14.84M	-23.96M	-26.73M
Depreciation & Amortization	0	0	0	9.27K	12.04K	10.88K
Stock-Based Compensation	775.25K	219.25K	511.08K	0	1.08M	841.87K
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	2.21M	-9.22M	3.37M	1.55M	51.97K	14.79M
Working Capital Changes	561.79K	1.32M	-2.22M	-277.52K	1.78M	-3.48M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	505.41K	556.27K	-866.01K	-787.89K	1.45M	-946K
Cash from Investing+	0	0	-250K	-536.84K	0	-14.76M
Capital Expenditures	0	0	-250K	-536.84K	0	-7.32K
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	-14.75M
Cash from Financing+	1.96M	1.15M	58.39M	-102.07K	0	109.29M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-2.84M	-1.03M	-9.05M	-14.09M	-21.05M	-29.31M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	0.64%	-7.75%	-0.56%	-0.49%	-0.39%
FCF per Share	-0.26	-0.09	-3.19	-0.88	-1.32	-0.50
FCF Conversion (FCF/Net Income)	0.44x	-0.16x	0.84x	0.91x	0.88x	0.54x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-66.71%	-35.74%	-102.79%	-49.89%
Debt / Equity	-	-	-	0.00x	-	0.00x
Interest Coverage	-4.89x	-3.89x	-163.85x	-28.11x	-	-
FCF Conversion	0.44x	-0.16x	0.84x	0.91x	0.88x	0.54x

Frequently Asked Questions

Growth & Financials

Context Therapeutics Inc. (CNTX) grew revenue by 0.0% over the past year. Growth has been modest.

Context Therapeutics Inc. (CNTX) reported a net loss of $26.4M for fiscal year 2024.

Dividend & Returns

Context Therapeutics Inc. (CNTX) has a return on equity (ROE) of -49.9%. Negative ROE indicates the company is unprofitable.

Context Therapeutics Inc. (CNTX) had negative free cash flow of $22.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener